AzTrials
AzTrials

Corona Virus InfectionNCT04758039

Clinical Characteristics and In-hospital Death of a Chilean COVID-19 Prospective Cohort

An observational study of Corona Virus Infection, run by University of Chile at 1 site in Chile.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The investigators planned to examine a cohort of admitted patients at University of Chile Clinical Hospital with COVID-19 diagnosis. Authors report data on mortality, ICU admission, need of invasive mechanical ventilation, awake and ventilated prone positioning, use of High Flow Nasal Cannula, Thromboembolic disease… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Corona Virus Infection
How many people
395 participants
Where
1 siteChile
Study dates
13 Mar 2020to 10 Jul 2020
How long will I take part?
28 Days
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adults with confirmed infection by SARS-CoV 2 Since the purpose of this study was to include all the patients admitted during the first 100 days of the pandemic, no sample size calculation was performed.

Who may be able to join

  • Patients over 18 years
  • Diagnosis of COVID-19 defined by clinical findings of acute respiratory illness (as per WHO guidelines) together with i) a positive result on reverse transcriptase chain reaction polymerase (RT-PCR) assay performed on a nasopharyngeal swab; and/or ii) chest computed tomography (CT) with typical findings of COVID-19 and absence of an alternative diagnosis

Who cannot join

  • Length of hospital stay less than 24 hours
  • Nosocomial SARS-CoV-2 infection
  • Asymptomatic patients admitted for causes not related to coronavirus infection regardless their admission RT-PCR result

Trial locations and contacts

1 site in 1 country.

Chile1 site
  • Hospital Clinico de la Universidad de Chile

    Santiago, Santiago Metropolitan

Other trials in Chile

About this study

Official title: Clinical Characteristics and In-hospital Death During the First 100 Days of the COVID-19 Pandemic in Chile: A Prospective Cohort Study From a University Hospital

The investigators planned to examine a cohort of admitted patients at University of Chile Clinical Hospital with COVID-19 diagnosis. Authors report data on mortality, ICU admission, need of invasive mechanical ventilation, awake and ventilated prone positioning, use of High Flow Nasal Cannula, Thromboembolic disease, Acute Kidney Injury (AKI) and Renal Replacement Therapy. Additionally, the risk of in-hospital death according to chronic disease burden and severity of illness at admission was assessed.

Read the detailed description

This is a prospective cohort study of adult inpatients at University of Chile Clinical Hospital, located in Santiago, Chile. We enrolled all patients aged over 18 years detected with COVID-19 admitted to the emergency department between March 1-June 11, 2020 through prospective identification using daily admission records. Briefly, COVID-19 diagnosis was made when patients had clinical findings of acute respiratory illness together with i) a positive result on reverse transcriptase chain reaction polymerase (RT-PCR) assay performed on a nasopharyngeal swab; and/or ii) chest computed tomography (CT) with typical findings of COVID-19 and absence of an alternative diagnosis. We intended to include all admitted patients during the first 100 days of the pandemic; therefore, no sample size calculation was performed. We excluded patients with length of stay less than 24 hours, nosocomial SARS-CoV-2 infection, and asymptomatic patients admitted for causes unrelated to SARS-CoV-2 infection regardless of their admission RT-PCR result.

All data were prospectively recorded for each included patient at admission and then daily until the end of the follow-up. Records were consulted by trained physicians, using a standardized data collection form, and then checked by a team of four physicians. Data discrepancy was agreed between the same clinicians.

Recorded data included demographic characteristics, comorbidities, disease onset time, associated symptoms, vital signs at the emergency department, laboratory test performed within 24 hours after admission, characteristics of the first chest CT, medication and supportive care provided, and length of stay at the hospital.

The use of antibiotics, antiviral therapy, corticosteroids, advanced oxygen delivery techniques, need for invasive mechanical ventilation (IMV), awake and ventilated prone position, use of vasopressor drugs, and need for renal replacement therapy (RRT) were explicitly recorded. Clinical management and use of these therapies were based on national recommendations from scientific societies and local protocols. Outcome collection and assignment are explained below.

Laboratory confirmation of SARS-CoV-2 infection was made using RT-PCR of nasopharyngeal swabs. All laboratory, microbiologic, and radiologic assessments were performed at the discretion of the treating physicians who were encouraged to follow local clinical guidelines. Film-array on the nasopharyngeal swab was performed for viral co-infection assessment, and urinary antigens. (pneumococcal and legionella) and blood cultures were performed for bacterial co-infection assessment. Chest radiographs and CT were also performed for all inpatients by experienced radiologists and classified as COVID-19-unrelated, typical or atypical pattern, and unspecified.

Keywords
Coronavirus Infection, COVID-19, SARS-CoV 2, Clinical Scenarios, Hospitalism, Hospitalist, Teaching Hospital, Awake Prone Positioning, Ventilated Prone Positioning, High Flow Nasal Cannula, HFNC, Invasive Mechanical Ventilation, Modified Charlson Comorbidity Index, Charlson Comorbidity Index, In-Hospital Mortality
Medical subject headings
Coronavirus Infections, COVID-19

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. In hospital Mortality

    Death while hospitalized

    Measured: March 13th to July 10th 2020

Secondary outcomes (5)
  1. Admission to an intensive care unit (ICU)

    Admission to an intensive care unit (ICU)

    Measured: March 13th to July 10th 2020

  2. Use of invasive mechanical ventilation (IMV)

    Days from admission and length of IMV

    Measured: March 13th to July 10th 2020

  3. Presence of thromboembolic disease (deep vein thrombosis, pulmonary embolism or both)

    Described as a positive US exploration of the arms or legs, and a positive CT Scan

    Measured: March 13th to July 10th 2020

  4. Acute kidney injury (AKI)

    AKI, as per defined by the Kidney Disease Improving Global Outcomes (KDIGO) initiative

    Measured: March 13th to July 10th 2020

  5. Renal replacement therapy (RRT).

    Days from admission and length of RRT

    Measured: March 13th to July 10th 2020

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Feb 2021
  2. Study start13 Mar 2020
  3. Primary completion10 Jul 2020
  4. Study completion10 Jul 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
395 participants (actual)
Target duration
28 Days
IDs, dates and publications
ClinicalTrials.gov ID
NCT04758039
Sponsor's protocol ID
OAIC N° 1119/20
Status last verified
Feb 2021
First submitted
15 Feb 2021
Last updated
18 Feb 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Anonymized data will be shared upon request

Questions about this trial

What is this clinical trial studying?

An observational study of Corona Virus Infection, run by University of Chile at 1 site in Chile.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Chile. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

In hospital Mortality (time frame: March 13th to July 10th 2020). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in